Teva: Branded Momentum Clashes With Generic Declines And IRA Headwinds
Teva's business is encountering headwinds, including declining U.S. generics revenue. Read what this biotech plans to do in ...
Teva price target lowered to $20 from $23 at BofA
BofA lowered the firm’s price target on Teva (TEVA) to $20 from $23 and keeps a Buy rating on the shares. The firm revised lower its FY26 and ...